ENDRA Life Sciences Inc.
NDRA
$6.46
$1.1922.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -10.57% | 25.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -31.76% | 34.01% | |||
| Operating Income | 31.76% | -34.01% | |||
| Income Before Tax | 112.19% | 58.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 112.19% | 58.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 112.19% | 58.62% | |||
| EBIT | 31.76% | -34.01% | |||
| EBITDA | 31.84% | -34.27% | |||
| EPS Basic | 111.05% | 61.70% | |||
| Normalized Basic EPS | 110.29% | 61.44% | |||
| EPS Diluted | 105.49% | 61.70% | |||
| Normalized Diluted EPS | 105.50% | 61.44% | |||
| Average Basic Shares Outstanding | 10.37% | 8.02% | |||
| Average Diluted Shares Outstanding | 106.34% | 8.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||